Development and full validation of an innovative HPLC-diode array detection technique to simultaneously quantify lacosamide, levetiracetam and zonisamide in human plasma. (21st March 2018)

• Record Type: Journal Article
• Authors: Gonçalves, Joana; Alves, Gilberto; Bicker, Joana; Falcão, Amílcar; Fortuna, Ana
• Is Part Of: Bioanalysis. Volume 10:Number 8(2018)
• Page Start: 541
• Page End: 557
• Publication Date: 2018-03-21
• Subjects: Drugs -- Analysis -- Periodicals; 615.19005
• DOI: 10.4155/bio-2017-0199
• Languages: English
• ISSNs: 1757-6180

Abstract

Aim: To implement pharmacokinetic drug monitoring and individualize the posology of new antiepileptic drugs, the first HPLC-diode array detection method was developed and validated to simultaneously quantify lacosamide, levetiracetam and zonisamide in human plasma.Materials & methods: Preceded by a reproducible liquid–liquid extraction, chromatographic separation was achieved by using a C18 column of 5 cm length and a mobile phase of water/acetonitrile. Full validation was performed according to international guidelines.Results: The method was linear within 0.5–30, 2.5–40.0 and 0.5–50.0 μg ml -1 for lacosamide, levetiracetam and zonisamide, respectively (r 2 ≥ 0.998), accurate (-12.411–8.303%), precise (≤8.875%).Conclusion: This innovative HPLC-diode array detection method was successfully employed in clinical practice and is expected to empower epileptic patients with a personalized pharmacotherapy service.